Guo MY, et al. - Using evidence generated from a pooled analysis of current studies, researchers evaluated the 1-year visual acuity (VA) outcomes in response to aflibercept therapy in neovascular age-related macular degeneration and identified the factors affecting treatment response. Compared to an irregular posology, findings demonstrated larger VA gains with regular posology and decreased effect size as age increased. At 12 months, improved VA outcomes were suggested in patients with wet age-related macular degeneration (AMD) for 2.0 mg aflibercept, comparable to but slightly lower than landmark trials. A trend with improved outcomes was demonstrated by increased injection frequency and younger age.